Biocartis and VIB join forces to develop unique diagnostic cancer test
AngioDynamics to lay off up to 100 in consolidation plan
TG Therapeutics launches combination clinical trial of TG-1101 and ibrutinib in patients with select b-cell malignancies
For daily banking news and anonymous message boards, check out the new site cafebanking.com.
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24h |
Increase |
|---|---|---|---|
| Shanghai Pharmaceutical | 9 | 49 | 444 % |
| Amyris | 1 | 5 | 400 % |
| Calypso Medical | 3 | 12 | 300 % |
| Concentric Medical | 1 | 4 | 300 % |
| Vertex | 13 | 50 | 285 % |
| Specials Laboratory | 2 | 7 | 250 % |
| Eleme Medical | 2 | 7 | 250 % |
| Dendreon | 1 | 3 | 200 % |
| Edge Therapeutics | 3 | 9 | 200 % |
| Actelion | 3 | 9 | 200 % |
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| Biocartis | 3 | 39 | 1200 % |
| Spectrum Pharmaceuticals | 4 | 51 | 1175 % |
| TG Therapeutics | 4 | 37 | 825 % |
| AngioDynamics | 7 | 51 | 629 % |
| Caliper Life Sciences | 2 | 14 | 600 % |
| Alvogen | 1 | 7 | 600 % |
| CytomX | 3 | 21 | 600 % |
| Rigel Pharmaceuticals | 2 | 13 | 550 % |
| CelSci | 2 | 13 | 550 % |
| Cel-Sci | 9 | 56 | 522 % |